Table 2.

The definitions of the terms BCG relapse, BCG-refractory and BCG-intolerant

BCG Relapse	- A recurrence of tumour after a period of disease-free status. - The time point for evaluation should be at 3 months for papillary tumours and 6 months for CIS (except when disease progression was observed at 3 months) - Relapse can be further stratified as early (<1 year after treatment), intermediate (1–2 years) or late (>2 years), as the disease-free interval is a prognostic variable; early-relapsing patients are more likely to progress and late-relapsing patients can possibly derive some benefit from reinduction with BCG.
BCG-refractory	- BCG-refractory is the persistence of disease after adequate induction and one maintenance course of BCG. - This category includes any progression in stage or grade by 3 months if patients received induction BCG only
BCG-intolerant	- BCG-intolerant is defined as the inability to tolerate at least one full induction course of BCG. - The tumour recurs largely because of inadequate therapy, which does not have the same negative prognostic implications as a true BCG failure.

BCG: Bacillus Calmette Guerin; CIS: carcinoma in situ